Abstract
Vaccines consisting of transgenic plant-derived antigens offer a new strategy for development of safe, inexpensive vaccines. The vaccine antigens can be eaten with the edible part of the plant or purified from plant material. In phase 1 clinical studies of prototype potato- and corn-based vaccines, these vaccines have been safe and immunogenic without the need for a buffer or vehicle other than the plant cell. Transgenic plant technology is attractive for vaccine development because these vaccines are needle-less, stable, and easy to administer. This chapter examines some early human studies of oral transgenic plant-derived vaccines against enterotoxigenic Escherichia coli infection, norovirus, and hepatitis B.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Administration, Oral
-
Clinical Trials as Topic
-
Escherichia coli Vaccines / administration & dosage
-
Escherichia coli Vaccines / adverse effects
-
Escherichia coli Vaccines / biosynthesis
-
Escherichia coli Vaccines / immunology
-
Humans
-
Plants, Genetically Modified / genetics*
-
Plants, Genetically Modified / metabolism*
-
Solanum tuberosum / genetics
-
Solanum tuberosum / metabolism
-
Vaccines, Subunit / administration & dosage
-
Vaccines, Subunit / adverse effects
-
Vaccines, Subunit / biosynthesis*
-
Vaccines, Subunit / immunology*
-
Viral Vaccines / administration & dosage
-
Viral Vaccines / adverse effects
-
Viral Vaccines / biosynthesis
-
Viral Vaccines / immunology
-
Zea mays / genetics
-
Zea mays / metabolism
Substances
-
Escherichia coli Vaccines
-
Vaccines, Subunit
-
Viral Vaccines